Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $1,347,216.52 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Anatol Kreitzer sold 45,422 shares of Maplight Therapeutics stock in a transaction on Monday, April 27th. The stock was sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the transaction, the insider directly owned 211,190 shares in the company, valued at $6,263,895.40. This represents a 17.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maplight Therapeutics Stock Down 3.7%

MPLT opened at $30.70 on Friday. The stock has a market cap of $1.30 billion and a P/E ratio of -0.77. The business’s fifty day moving average price is $22.19. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, sell-side analysts forecast that Maplight Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Maplight Therapeutics

Several institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new position in Maplight Therapeutics in the fourth quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Maplight Therapeutics in the fourth quarter valued at approximately $70,000. New York State Common Retirement Fund purchased a new position in Maplight Therapeutics in the fourth quarter valued at approximately $93,000. MetLife Investment Management LLC purchased a new position in Maplight Therapeutics in the fourth quarter valued at approximately $172,000. Finally, Walleye Capital LLC purchased a new position in Maplight Therapeutics in the fourth quarter valued at approximately $205,000.

Analyst Ratings Changes

MPLT has been the topic of a number of research analyst reports. Weiss Ratings initiated coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. TD Cowen initiated coverage on Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a “buy” rating on the stock. Canaccord Genuity Group initiated coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 target price on the stock. Wall Street Zen downgraded Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Needham & Company LLC started coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.67.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.